Du CZ, Chen YC, Cai Y, Xue WC, Gu J. Oncologic outcomes of primary and post-irradiated early stage rectal cancer: A retrospective cohort study. World J Gastroenterol 2011; 17(27): 3229-3234 [PMID: 21912472 DOI: 10.3748/wjg.v17.i27.3229]
Corresponding Author of This Article
Jin Gu, MD, FACS, Professor and Chairman, Department of Colorectal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. zlguj@yahoo.com.cn
Article-Type of This Article
Original Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 21, 2011; 17(27): 3229-3234 Published online Jul 21, 2011. doi: 10.3748/wjg.v17.i27.3229
Table 1 Characteristics of patients included in this study
Characteristic
Group
P value
Ypstage I (n = 45)
Pstage I (n = 39)
Gender
Male
28
21
0.437
Female
17
18
Age (yr)
< 60
19
10
0.111
> 60
26
29
Median
62
67
Distance from anal verge (cm)
≤ 5
20
9
0.040
> 5
25
30
Pretreatment serum CEA (ng/mL)
≤5
29
32
0.016
> 5
13
3
unknown
3
4
Surgery
APR
14
6
0.091
LAR
31
33
Clinical and pathologic stage
cT1-2N0
0
28
< 0.001
cT3-4N0
15
6
cTanyN+
30
5
pT1N0
5
14
0.007
pT2N0
40
25
Histological differentiation
High
3
15
< 0.001
Moderate
34
23
Poor
8
1
Lymphovascular invasion
Positive
0
1
0.464
Negative
45
38
NELN
< 12
27
23
0.924
≥ 12
18
16
Table 2 Oncologic outcomes of patients in two groups n (%)
Ypstage I
Pstage I
P value
Local recurrence rate
2 (4.4)
1 (2.6)
1.0001
Distant metastasis rate
6 (13.3)
3 (7.7)
0.4941
5-yr DFS rate
38 (84.4)
36 (92.3)
0.327
5-yr OS rate
40 (88.9)
36 (92.3)
0.692
Table 3 Correlation between clinical stage and disease progression in ypstage I group
Clinical stage
Disease progression (n)
OR (95% CI)
P value
Yes
No
cT3-4N0
3
12
0.31-8.43
0.6701
cTanyN+
4
26
Table 4 Correlation between adjuvant chemotherapy and disease progression in ypstage I group
Adjuvant chemotherapy
Disease progression (n)
OR (95% CI)
P value
Yes
No
Yes
2
17
0.09-2.87
0.6811
No
5
21
Table 5 Multivariate analysis of disease-free survival rate by COX model (forward method)
Variable
Hazard ratio
95% CI
P value
Pretreatment serum CEA
5.535
1.574-19.468
0.008
Distance from anal verge
0.715
0.453-1.130
0.064
Gender
0.483
0.174-1.337
0.154
Age
1.057
0.999-1.119
0.054
Neoadjuvant radiotherapy
0.490
0.176-1.362
0.244
Histological differentiation
1.161
0.452-2.980
0.929
Pathologic T stage
0.827
0.232-0.953
0.271
Lymphovascular invasion
1.643
0.164-16.480
0.829
NELN
0.946
0.880-1.017
0.244
Adjuvant chemotherapy
1.381
0.512-3.725
0.670
Citation: Du CZ, Chen YC, Cai Y, Xue WC, Gu J. Oncologic outcomes of primary and post-irradiated early stage rectal cancer: A retrospective cohort study. World J Gastroenterol 2011; 17(27): 3229-3234